EUVIMEDEUVIMED entdecken
Leitlinie

Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025

Mário Dinis-Ribeiro, Diogo Libânio iD, Hugo Uchima, Manon C W Spaander iD, Jan Bornschein, Tamara Matysiak-Budnik, Georgios Tziatzios iD, João Santos-Antunes iD, Miguel Areia iD, Nicolas Chapelle iD, Gianluca Esposito iD, Gloria Fernandez-Esparrach iD und 18 weitere

Endoscopy · 2025-05 · 57 (05) · 504-554

DOI: 10.1055/a-2529-5025 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Endoscopy, online erschienen am 20.03.2025. Verfasst von Mário Dinis-Ribeiro und 29 weiteren Autor:innen. Beteiligte Einrichtung: Precancerous Lesions and Early Cancer Management Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Group), Portuguese Insti…. Hauptthemen laut MEDLINE: Precancerous Conditions, Stomach Neoplasms, Gastroscopy, Early Detection of Cancer. Die Arbeit wurde bisher 232-mal zitiert (Crossref) und nennt 447 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Main Recommendations At a population level, the European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter and Microbiota Study Group (EHMSG), and the European Society of Pathology (ESP) suggest endoscopic screening for gastric cancer (and precancerous conditions) in high-risk regions (age-standardized rate [ASR] > 20 per 100 000 person-years) every 2 to 3 years or, if cost–effectiveness has been proven, in intermediate risk regions (ASR 10–20 per 100 000 person-years) every 5 years, but not in low-risk regions (ASR < 10). ESGE/EHMSG/ESP recommend that irrespective of country of origin, individual gastric risk assessment and stratification of precancerous conditions is recommended for first-time gastroscopy. ESGE/EHMSG/ESP suggest that gastric cancer screening or surveillance in asymptomatic individuals over 80 should be discontinued or not started, and that patients’ comorbidities should be considered when treatment of superficial lesions is planned. ESGE/EHMSG/ESP recommend that a high quality endoscopy including the use of virtual chromoendoscopy (VCE), after proper training, is performed for screening, diagnosis, and staging of precancerous conditions (atrophy and intestinal metaplasia) and lesions (dysplasia or cancer), as well as after endoscopic therapy. VCE should be used to guide the sampling site for biopsies in the case of suspected neoplastic lesions as well as to guide biopsies for diagnosis and staging of gastric precancerous conditions, with random biopsies to be taken in the absence of endoscopically suspected changes. When there is a suspected early gastric neoplastic lesion, it should be properly described (location, size, Paris classification, vascular and mucosal pattern), photodocumented, and two targeted biopsies taken. ESGE/EHMSG/ESP do not recommend routine performance of endoscopic ultrasonography (EUS), computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT prior to endoscopic resection unless there are signs of deep submucosal invasion or if the lesion is not considered suitable for endoscopic resection. ESGE/EHMSG/ESP recommend endoscopic submucosal dissection (ESD) for differentiated gastric lesions clinically staged as dysplastic (low grade and high grade) or as intramucosal carcinoma (of any size if not ulcerated or ≤ 30 mm if ulcerated), with EMR being an alternative for Paris 0-IIa lesions of size ≤ 10 mm with low likelihood of malignancy. ESGE/EHMSG/ESP suggest that a decision about ESD can be considered for malignant lesions clinically staged as having minimal submucosal invasion if differentiated and ≤ 30 mm; or for malignant lesions clinically staged as intramucosal, undifferentiated and ≤ 20 mm; and in both cases with no ulcerative findings. ESGE/EHMSG/ESP recommends patient management based on the following histological risk after endoscopic resection: Curative/very low-risk resection (lymph node metastasis [LNM] risk < 0.5 %–1 %): en bloc R0 resection; dysplastic/pT1a, differentiated lesion, no lymphovascular invasion, independent of size if no ulceration and ≤ 30 mm if ulcerated. No further staging procedure or treatment is recommended. Curative/low-risk resection (LNM risk < 3 %): en bloc R0 resection; lesion with no lymphovascular invasion and: a) pT1b, invasion ≤ 500 µm, differentiated, size ≤ 30 mm; or b) pT1a, undifferentiated, size ≤ 20 mm and no ulceration. Staging should be completed, and further treatment is generally not necessary, but a multidisciplinary discussion is required. Local-risk resection (very low risk of LNM but increased risk of local persistence/recurrence): Piecemeal resection or tumor-positive horizontal margin of a lesion otherwise meeting curative/very low-risk criteria (or meeting low-risk criteria provided that there is no submucosal invasive tumor at the resection margin in the case of piecemeal resection or tumor-positive horizontal margin for pT1b lesions [invasion ≤ 500 µm; well-differentiated; size ≤ 30 mm, and VM0]). Endoscopic surveillance/re-treatment is recommended rather than other additional treatment. High-risk resection (noncurative): Any lesion with any of the following: (a) a positive vertical margin (if carcinoma) or lymphovascular invasion or deep submucosal invasion (> 500 µm from the muscularis mucosae); (b) poorly differentiated lesions if ulceration or size > 20 mm; (c) pT1b differentiated lesions with submucosal invasion ≤ 500 µm with size > 30 mm; or (d) intramucosal ulcerative lesion with size > 30 mm. Complete staging and strong consideration for additional treatments (surgery) in multidisciplinary discussion. ESGE/EHMSG/ESP suggest the use of validated endoscopic classifications of atrophy (e. g. Kimura–Takemoto) or intestinal metaplasia (e. g. endoscopic grading of gastric intestinal metaplasia [EGGIM]) to endoscopically stage precancerous conditions and stratify the risk for gastric cancer. ESGE/EHMSG/ESP recommend that biopsies should be taken from at least two topographic sites (2 biopsies from the antrum/incisura and 2 from the corpus, guided by VCE) in two separate, clearly labeled vials. Additional biopsy from the incisura is optional. ESGE/EHMSG/ESP recommend that patients with extensive endoscopic changes (Kimura C3 + or EGGIM 5 +) or advanced histological stages of atrophic gastritis (severe atrophic changes or intestinal metaplasia, or changes in both antrum and corpus, operative link on gastritis assessment/operative link on gastric intestinal metaplasia [OLGA/OLGIM] III/IV) should be followed up with high quality endoscopy every 3 years, irrespective of the individual’s country of origin. ESGE/EHMSG/ESP recommend that no surveillance is proposed for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history, incomplete intestinal metaplasia, persistent H. pylori infection). This group constitutes most individuals found in clinical practice. ESGE/EHMSG/ESP recommend H. pylori eradication for patients with precancerous conditions and after endoscopic or surgical therapy. ESGE/EHMSG/ESP recommend that patients should be advised to stop smoking and low-dose daily aspirin use may be considered for the prevention of gastric cancer in selected individuals with high risk for cardiovascular events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precancerous ConditionsStomach NeoplasmsGastroscopyEarly Detection of CancerHumansRisk AssessmentEuropeHelicobacter InfectionsGastric MucosaSocieties, MedicalBiopsy

Autor:innen und Institutionen

  • Precancerous Lesions and Early Cancer Management Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Group), Portuguese Institute of Oncology of Porto (IPO Porto)/Porto Comprehensive Cancer Cente…
  • Gastroenterology Department, Portuguese Institute of Oncology of Porto, Porto, Portugal.
  • Endoscopy Unit Gastroenterology Department Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Endoscopy Unit, Teknon Medical Center, Barcelona, Spain.
  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Medical Research Council Translational Immune Discovery Unit (MRC TIDU), Weatherall Institute of Molecular Medicine (WIMM), Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

ORCID-Profile: Diogo Libânio, Manon C W Spaander, Georgios Tziatzios, João Santos-Antunes, Miguel Areia, Nicolas Chapelle, Gianluca Esposito, Gloria Fernandez-Esparrach, Lumir Kunovsky, Mónica Garrido, Ilja Tacheci, Pedro Pimentel-Nunes, Raf Bisschops, Konstantinos Triantafyllou

Zitieren

APA

Dinis-Ribeiro, M., Libânio, D., Uchima, H., Spaander, M. C. W., Bornschein, J., Matysiak-Budnik, T., Tziatzios, G., Santos-Antunes, J., Areia, M., Chapelle, N., Esposito, G., Fernandez-Esparrach, G., Kunovsky, L., Garrido, M., Tacheci, I., Link, A., Marcos, P., Marcos-Pinto, R., Moreira, L., …, & Kuipers, E. J. (2025). Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy, 57(05), 504-554. https://doi.org/10.1055/a-2529-5025

Vancouver

Dinis-Ribeiro M, Libânio D, Uchima H, Spaander MCW, Bornschein J, Matysiak-Budnik T, et al. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy. 2025;57(05):504-554. doi:10.1055/a-2529-5025

BibTeX
@article{DinisRibeiro2025,
  author = {Dinis-Ribeiro, Mário and Libânio, Diogo and Uchima, Hugo and Spaander, Manon C W and Bornschein, Jan and Matysiak-Budnik, Tamara and Tziatzios, Georgios and Santos-Antunes, João and Areia, Miguel and Chapelle, Nicolas and Esposito, Gianluca and Fernandez-Esparrach, Gloria and Kunovsky, Lumir and Garrido, Mónica and Tacheci, Ilja and Link, Alexander and Marcos, Pedro and Marcos-Pinto, Ricardo and Moreira, Leticia and Pereira, Ana Carina and Pimentel-Nunes, Pedro and Romanczyk, Marcin and Fontes, Filipa and Hassan, Cesare and Bisschops, Raf and Feakins, Roger and Schulz, Christian and Triantafyllou, Konstantinos and Carneiro, Fatima and Kuipers, Ernst J},
  title = {Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025},
  journal = {Endoscopy},
  year = {2025},
  volume = {57},
  number = {05},
  pages = {504--554},
  doi = {10.1055/a-2529-5025}
}
Kostenlos starten →